FDA approves Merck's Lipfendra, the first oral PCSK9 inhibitor

The FDA approved Merck's Lipfendra (enlicitide) in July 2026, the first oral PCSK9 inhibitor on the U.S. market. Reuters also covered the approval in mid-July. In two Phase 3 trials, the drug lowered LDL cholesterol by up to 60% in some patient groups. Until now, that kind of drop has only been available through injectable biologics that cost many times more.

Lipfendra lands in the same year the American Heart Association and American College of Cardiology updated their guidelines. Adults at risk of cardiovascular disease should now target an LDL level under 70 milligrams per deciliter. High-risk patients should aim for under 55. Most Americans, the guidelines say, should be screened at least once every five years. A pill that hits the new targets at a lower list price lands in the same window the guidelines opened.

PCSK9 inhibitors are a different class from statins. Statins slow the liver's production of LDL, the cholesterol that builds up in artery walls. PCSK9 inhibitors work downstream. They block a protein on liver cells that would otherwise keep LDL circulating. Repatha and Praluent, the two injectable PCSK9 drugs, have been on the U.S. market for about a decade. Their list prices have kept them out of reach for most patients who could have used them. Enlicitide, according to Merck, was designed to do the same job as a once-daily 20-milligram pill taken on an empty stomach in the morning. The wholesale list price is $315 for a 30-day supply, a fraction of what the injectables cost.

Merck discovered lovastatin, the first statin, in 1987, and has stayed at the center of cholesterol treatment since. The arrival of the first oral PCSK9 inhibitor from the same company is not a sign that the statin era is ending. The two classes work at different points in the same pathway. A patient who tolerates a moderate statin may not need a PCSK9 inhibitor. A patient with the genetic form of high cholesterol, or someone whose LDL has stayed stubbornly high on a statin, is the more obvious candidate.

The efficacy data come from two Phase 3 trials, CORALreef Lipids and CORALreef HeFH. In CORALreef Lipids, patients with a mean baseline LDL of 96 mg/dL saw a 56% reduction versus placebo at week 24, and roughly 60% in a post-hoc analysis. In CORALreef HeFH, the trial in patients with the genetic form of high cholesterol, baseline LDL averaged 119 mg/dL and the reduction at 24 weeks was 59%. Side effects in CORALreef Lipids tracked with placebo. In CORALreef HeFH, diarrhea hit 7% of patients on enlicitide versus 2% on placebo, and dizziness hit 9% versus 4%.

A 60% LDL drop is a surrogate marker. The drug lowers a cholesterol number, not a heart attack. Merck is running a cardiovascular outcomes trial called CORALreef Outcomes, registered as NCT06008756, that has enrolled more than 14,500 patients and is still reading out. Until that data lands, no one can say whether the LDL reduction translates into fewer heart attacks and strokes. "The oral PCSK9 pathway is a credible comparator to the injectables on LDL lowering," said Eric Topol, "but until the outcomes trial reports, that's all we know it does."

At $315 a month at list, enlicitide is closer to a phone bill than a car payment. Net pricing, insurance coverage, and out-of-pocket cost will vary, and none of that is settled yet. The March guidelines have moved LDL targets lower for at-risk adults, and the question worth asking a clinician is whether the new numbers apply and whether a new oral option belongs in the plan.

The next milestone is the CORALreef Outcomes readout. Until it reports, Lipfendra is a $315-a-month pill that drops LDL by up to 60% in trials. The open question is the same one the injectable PCSK9s have carried for a decade: whether the biomarker translates into fewer heart attacks and strokes.